DE122009000066I1 - Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen - Google Patents

Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen

Info

Publication number
DE122009000066I1
DE122009000066I1 DE122009000066C DE122009000066C DE122009000066I1 DE 122009000066 I1 DE122009000066 I1 DE 122009000066I1 DE 122009000066 C DE122009000066 C DE 122009000066C DE 122009000066 C DE122009000066 C DE 122009000066C DE 122009000066 I1 DE122009000066 I1 DE 122009000066I1
Authority
DE
Germany
Prior art keywords
treatment
conditions
neuromuscular disorders
botulinum serotypes
various botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE122009000066C
Other languages
English (en)
Other versions
DE122009000066I2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE122009000066I1 publication Critical patent/DE122009000066I1/de
Publication of DE122009000066I2 publication Critical patent/DE122009000066I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE122009000066C 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen Active DE122009000066I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7504893A 1993-06-10 1993-06-10
DE69435235T DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen

Publications (2)

Publication Number Publication Date
DE122009000066I1 true DE122009000066I1 (de) 2010-02-04
DE122009000066I2 DE122009000066I2 (de) 2010-12-30

Family

ID=22123211

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69435235T Expired - Lifetime DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435253T Expired - Lifetime DE69435253D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE122009000066C Active DE122009000066I2 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69435235T Expired - Lifetime DE69435235D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69435254T Expired - Lifetime DE69435254D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69435253T Expired - Lifetime DE69435253D1 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69435284T Expired - Lifetime DE69435284D1 (de) 1993-06-10 1994-06-07 Behandlung neuromuskulärer Erkrankungen und Zustände mit verschiedenem Botulin-Serotyp
DE69429619T Expired - Lifetime DE69429619T2 (de) 1993-06-10 1994-06-07 Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e

Country Status (9)

Country Link
US (3) US6872397B2 (de)
EP (7) EP1941898B1 (de)
JP (4) JPH08511536A (de)
AU (1) AU689115B2 (de)
CA (3) CA2310845C (de)
DE (6) DE69435235D1 (de)
ES (5) ES2335281T3 (de)
HK (1) HK1061648A1 (de)
WO (1) WO1994028922A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
DE69435235D1 (de) * 1993-06-10 2009-10-15 Allergan Inc Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69434443T2 (de) * 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE239491T1 (de) * 1995-06-06 2003-05-15 L Bruce Pearce Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
CA2319113A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
WO2004078199A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
EP2316847A3 (de) * 2005-03-15 2012-01-18 Allergan, Inc. Modifizierte Clostridientoxine mit erhöhter Targeting-Kapazität für endogene Clostridientoxin-Rezeptorsysteme
DK1920248T3 (da) 2005-04-05 2010-12-13 Allergan Inc Clostridialt-toksin-aktivitetsassays
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7608275B2 (en) * 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
JPWO2009123174A1 (ja) * 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
WO2011056684A2 (en) 2009-10-27 2011-05-12 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
CN104321048B (zh) 2012-04-13 2019-01-11 路博润高级材料公司 抑制神经元胞吐的化合物(ii)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN116333068A (zh) 2015-01-09 2023-06-27 益普生生物创新有限公司 阳离子神经毒素
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (de) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Herstellung von aktivierten clostridien-neurotoxinen
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2373454A (en) * 1943-07-09 1945-04-10 Squibb & Sons Inc Method of preparing tetanus toxin
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US3132995A (en) * 1961-10-20 1964-05-12 Carter Prod Inc Endotoxin fractions and method for producing same
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
FR2692475B1 (fr) 1992-06-19 2000-04-21 Montpellier Chirurgie Prothese totale du genou.
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
DE69435235D1 (de) * 1993-06-10 2009-10-15 Allergan Inc Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69434443T2 (de) 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung

Also Published As

Publication number Publication date
US20020010138A1 (en) 2002-01-24
DE69435235D1 (de) 2009-10-15
US20010012833A1 (en) 2001-08-09
CA2164866A1 (en) 1994-12-22
WO1994028922A1 (en) 1994-12-22
EP1166793A1 (de) 2002-01-02
EP1941898B1 (de) 2010-03-17
JP2005281317A (ja) 2005-10-13
EP1941898A3 (de) 2008-11-05
ES2335281T3 (es) 2010-03-24
JPH08511536A (ja) 1996-12-03
EP1508336B1 (de) 2009-11-18
ES2335662T3 (es) 2010-03-31
CA2164866C (en) 2001-09-11
EP1374886B1 (de) 2009-09-02
EP1508336A1 (de) 2005-02-23
AU7087894A (en) 1995-01-03
DE69435254D1 (de) 2009-12-31
ES2168302T3 (es) 2002-06-16
EP1374886A3 (de) 2004-02-11
HK1061648A1 (en) 2004-09-30
ES2329232T3 (es) 2009-11-24
EP1099445A2 (de) 2001-05-16
EP1941898A2 (de) 2008-07-09
JP2010111703A (ja) 2010-05-20
CA2332406C (en) 2005-01-04
CA2310845A1 (en) 1994-12-22
EP1099445A3 (de) 2001-09-05
ES2341140T3 (es) 2010-06-15
US6872397B2 (en) 2005-03-29
DE69429619T2 (de) 2002-09-12
DE122009000066I2 (de) 2010-12-30
EP0702561A1 (de) 1996-03-27
AU689115B2 (en) 1998-03-26
EP1374886A2 (de) 2004-01-02
DE69429619D1 (de) 2002-02-14
JP2011256193A (ja) 2011-12-22
EP0702561B1 (de) 2002-01-09
DE69435284D1 (de) 2010-04-29
CA2332406A1 (en) 1994-12-22
EP1512411A1 (de) 2005-03-09
CA2310845C (en) 2001-05-15
EP1512411B1 (de) 2009-11-18
DE69435253D1 (de) 2009-12-31
US20050129716A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
DE69435235D1 (de) Behandlung von neuromuskularen Störungen und Zuständen mit verschiedenen botulinen Serotypen
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
ATE218360T1 (de) Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
DE69220679T2 (de) Antibakterielles mittel und behandlung von gegenständen mit diesem
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69130437T2 (de) Gerät mit neuronalen Netzwerken zur Detektion und Behandlung von Arrythmien
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE69426690T2 (de) Behandlung von atrophischer Haut und Vagina
DE69212620T2 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69422016D1 (de) Behandlung und entschwelfung von stahl in reformierungsverfahren mit niedrigem schwefelgehalt
DE69429160T2 (de) Behandlung von textilprodukt
DE69306335T2 (de) Prevention und Behandlung von Atherosclerosis
DE69306831D1 (de) Behandlung von Flüssigkeiten
DE69429259D1 (de) Behandlung von futtern und fasergut
DE69501944D1 (de) Arzneimittel zur Vorbeugung oder Behandlung von chronischem Rheumatismus und Sepsis
AT400224B (de) Mittel zur behandlung und pflege von hufen
DE3881377T2 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
AU7319398A (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
DE69637316D1 (de) Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
DE69609820D1 (de) Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis
DE9318429U1 (de) Mittel zur Abwehr und/oder Behandlung von Insektenstichen
DE9319102U1 (de) Pflanzliches Mittel zur Behandlung von Hämorrhoiden und analen Fissuren
DE59408477D1 (de) Therapieeinrichtung zur behandlung von leiden des herzens und herznaher gefässe
ATE432709T1 (de) Behandlung von diabetes